The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context–Dependent Manner in Pediatric Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context–Dependent Manner in Pediatric Acute Lymphoblastic Leukemia

Published:2020-04-24 Issue:8 Volume:18 Page:1153-1165
ISSN:1541-7786
Container-title:Molecular Cancer Research
language:en
Short-container-title:Mol Cancer Res

Author:

Pierro Joanna,Saliba Jason^ORCID,Narang Sonali,Sethia Gunjan^ORCID,Saint Fleur-Lominy Shella,Chowdhury Ashfiyah,Qualls Anita,Fay Hannah,Kilberg Harrison L.,Moriyama Takaya,Fuller Tori J.^ORCID,Teachey David T.,Schmiegelow Kjeld^ORCID,Yang Jun J.,Loh Mignon L.,Brown Patrick A.,Zhang Jinghui^ORCID,Ma Xiaotu,Tsirigos Aristotelis^ORCID,Evensen Nikki A.,Carroll William L.

Funder

NCI

Leukemia and Lymphoma Society

Perlmutter Cancer Center

St. Baldrick's Foundation

NYU

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology,Molecular Biology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2;Journal of Medicinal Chemistry;2024-09-04

2. Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia;Nature Communications;2024-08-28

3. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;2024-02-27

4. SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia;Leukemia & Lymphoma;2023-10-24

5. Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2);Journal of Medicinal Chemistry;2023-08-14